About DSIP
DSIP is a nonapeptide first isolated from rabbit cerebral venous blood and studied for its effects on slow-wave sleep, stress response, and pain modulation. Most data is preclinical with limited Western clinical work.
Recovery
DSIP
Delta Sleep Inducing Peptide
A nonapeptide studied for sleep architecture and stress-response modulation.
PreclinicalResearch use only
Where to buy
Vendor offerings
Some links on this page are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.
Best $/mg
BioLongevity LabsTestedDSIP (Delta Sleep-Inducing Peptide) (5mg)
EVERYDAY$55.97
$11.19/mg · 5mg
Evidence level
Preclinical only
A nine-amino-acid peptide first isolated from sleep-induced rabbit cerebral blood in 1977. Studied for slow-wave sleep promotion and stress-axis modulation; clinical evidence remains thin and inconsistent.
Mechanism
Modulates GABAergic tone and stress hormones.
Researched benefits
Slow-wave sleep promotion
Early European EEG studies in rabbits and humans reported increases in delta (slow-wave) activity after intravenous DSIP. Effects were modest and not consistently reproduced across labs.
Stress and HPA modulation
Preclinical work suggests DSIP can blunt corticotropin and cortisol responses to acute stressors. Mechanism is incompletely characterized.
Possible analgesia
Some rodent models show reduced response to noxious stimuli, and a small clinical series reported reduced chronic-pain scores. Sample sizes are very small.
Withdrawal symptom reduction
Older European trials in opioid and alcohol withdrawal reported reduced subjective discomfort, but these studies were small, unblinded, and have not been replicated.
Risks & cautions
- high
Sparse modern safety data
Most clinical data comes from 1970s–1990s European work, often with vague endpoints. Long-term human safety is uncharacterized.
- moderate
Variable preparation quality
Research-grade DSIP is short-lived in solution and quality varies between suppliers. Degradation may explain inconsistent user reports.
- moderate
Paradoxical effects
Some users report stimulating rather than sedating effects, possibly via downstream catecholamine modulation. Not predictable from current literature.
- low
Injection-site reactions
Standard subcutaneous risks: erythema, transient bruising. Intranasal use can cause local irritation.
Dosing
100–500 mcg subcutaneously, 30–60 minutes before sleep, in short cycles.
- Conservative
- 100 mcg pre-sleep
- Standard
- 250 mcg pre-sleep
- Aggressive
- 500 mcg pre-sleep (not commonly exceeded)
Vial sizes
2mg / 5mg
Half-life
Short
Route
subcutaneous, intranasal
Reconstitute with bacteriostatic water and use within 1–2 weeks; DSIP is notoriously unstable in solution. Plasma half-life is on the order of minutes, so effects depend on receptor pharmacology rather than systemic accumulation.
Contraindications
- Pregnancy or breastfeeding — no data
- Active psychiatric medication regimens without supervision
- Children — no data
In depth
Background
DSIP (Delta Sleep Inducing Peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first identified by Schoenenberger and Monnier in 1977 from the cerebral venous blood of rabbits whose thalamus had been electrically stimulated to induce slow-wave sleep. The peptide was named for the EEG signature — increased delta-frequency activity — that appeared when it was transferred to a recipient animal.
Despite five decades of follow-up work, DSIP's endogenous receptor has never been definitively identified. It remains an "orphan" signaling peptide, which is a major reason mainstream sleep medicine has largely moved on from it.
Mechanism in depth
Proposed mechanisms include:
- Modulation of GABAergic tone in thalamocortical circuits, contributing to slow-wave EEG activity.
- Inhibition of CRH release at the hypothalamus, dampening HPA-axis output.
- Indirect effects on serotonergic and opioidergic tone — DSIP partially blocks naloxone-precipitated withdrawal signs in rodents.
- Possible direct membrane effects; some in vitro work suggests it modulates ion channel kinetics.
No single mechanism is settled. The lack of a cloned receptor means downstream signaling is inferred rather than mapped.
Human evidence
Sparse and aging:
- Several small EEG studies in the 1980s–1990s reported increases in delta and stage-3/4 sleep after intravenous or intranasal DSIP. Effect sizes were modest.
- Open-label series in chronic pain and withdrawal reported subjective improvement but lacked controls.
- A handful of insomnia trials with n in the 10–30 range produced mixed results.
No modern randomized controlled trial of DSIP for sleep has been published in a major journal. The peptide is not approved by any major regulatory body.
Animal evidence
More robust than the human literature:
- Reproducible EEG delta-power increases in rabbits and rats after intracerebroventricular administration.
- Attenuation of stress-induced cortisol/corticosterone in several species.
- Reduced opioid-withdrawal behaviors in morphine-dependent rodents.
Effects are often dose- and timing-sensitive, which is part of why translation has been difficult.
Stack synergy
Commonly stacked with:
- Epitalon — both target circadian/sleep biology through distinct mechanisms.
- Selank or Semax — anxiolytic peptides used as adjuncts for stress-driven insomnia.
- GHRPs / sermorelin — nocturnal GH pulse is reinforced by deeper slow-wave sleep, so users sometimes co-dose; evidence for synergy is anecdotal.
Avoid stacking with sedatives or alcohol; unpredictable additive CNS depression has been reported anecdotally.
Open questions
- What is DSIP's actual receptor? Without one, mechanism remains speculative.
- Why is the clinical record so inconsistent? Preparation stability is one suspect; species differences another.
- Is there a real signal for stress-axis modulation that warrants a properly powered modern trial?
References
- 1.Schoenenberger G.A., Monnier M. — Characterization of a delta-EEG-sleep-inducing peptide (PNAS, 1977)
- 2.Kovalzon V.M., Strekalova T.V. — Delta sleep-inducing peptide: a still unresolved riddle (Journal of Neurochemistry, 2006)
- 3.Graf M.V., Kastin A.J. — Delta-sleep-inducing peptide (DSIP): an update (Peptides, 1986)